Thursday, February 16, 2023, San Francisco, California, 7:15 PM – 9:15 PM Pacific Time (10:15 PM – 12:15 AM Eastern Time)

Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Prostate Cancer

Part 2 of a 3-Part CME Symposium Series Held in Conjunction with the 2023 ASCO Genitourinary Cancers Symposium

Location
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Program Schedule — Pacific Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 9:15 PM — Educational Dinner Meeting

Meeting Room
Yerba Buena – Salon 7 (Lower B2 Level)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.  
 
Faculty
Emmanuel S Antonarakis, MD
Clark Endowed Professor of Medicine
Division of Hematology, Oncology
and Transplantation
University of Minnesota
Minneapolis, Minnesota

Prof Karim Fizazi, MD, PhD
Head of Service and Full Professor
Institut Gustave Roussy
University of Paris Saclay
Villejuif, France

Maha Hussain, MD, FACP, FASCO
Genevieve Teuton Professor of Medicine
Division of Hematology/Oncology
Deputy Director
Robert H Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois


Matthew R Smith, MD, PhD
Claire and John Bertucci Endowed Chair
in Genitourinary Cancers
Professor of Medicine
Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Moderator
Alan H Bryce, MD
Chair, Division of Hematology and Medical Oncology
Chair, Genitourinary Disease Group
Mayo Clinic
Phoenix, Arizona


This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Merck, and Sanofi.
Program Schedule — Pacific Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 9:15 PM — Educational Dinner Meeting

MODULE 1: Management Approaches for Nonmetastatic Prostate Cancer

  • Mechanism of action of, published efficacy and safety findings with and FDA-approved indications for relugolix
  • Clinical implications of the STAMPEDE trial evaluating the efficacy and safety of abiraterone and prednisolone with or without enzalutamide with androgen deprivation therapy (ADT) for high-risk nonmetastatic prostate cancer
  • Efficacy and safety results from the Phase III PRESTO study evaluating ADT intensification with apalutamide with or without abiraterone for biochemically recurrent prostate cancer with a rapid PSA doubling time
  • Comparative designs of ongoing Phase III trials evaluating secondary hormonal agents for high-risk localized or locally advanced prostate cancer
  • Long-term efficacy outcomes with apalutamide, enzalutamide and darolutamide for nonmetastatic castration-resistant prostate cancer (CRPC)
  • Clinical, biologic and practical factors guiding the selection of enzalutamide, apalutamide and darolutamide for nonmetastatic CRPC

MODULE 2: Optimizing the Care of Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

  • Rationale for treatment intensification for patients with mHSPC; historical outcomes observed with ADT alone in this population and guideline-endorsed adjunctive strategies
  • Long-term efficacy and safety data, including overall survival findings, with docetaxel, abiraterone, enzalutamide or apalutamide in combination with ADT for mHSPC
  • Major findings from the Phase III PEACE-1 study of docetaxel with or without abiraterone with or without local radiation therapy for mHSPC; implications for clinical practice
  • Published efficacy and safety findings from the Phase III ARASENS trial demonstrating increased overall survival with darolutamide in combination with docetaxel and ADT for mHSPC
  • FDA approval of darolutamide with docetaxel/ADT and optimal incorporation of this combination into current disease management

MODULE 3: Current Therapeutic Options for Patients with Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • Key clinical and biologic factors in the selection of therapy for patients with newly diagnosed mCRPC; impact of earlier use of secondary hormonal therapy and chemotherapy on current disease management approaches
  • Key findings from clinical trial and real-world data sets exploring the efficacy and safety of sipuleucel-T; impact of patient age, race, PSA level and other factors on outcomes
  • Optimal patient selection for sipuleucel-T; importance of early identification of candidates
  • Biologic basis for combining PARP inhibitors with antiandrogen therapies for prostate cancer; rationale for the potential activity of these combinations in patients without homologous recombination repair (HRR) gene mutations
  • Available and emerging data (eg, from the PROpel, MAGNITUDE and TALAPRO-2 trials) with PARP inhibitors combined with secondary hormonal agents for previously untreated mCRPC
  • Rationale for the evaluation of CDK4/6 inhibitors among patients with mCRPC
  • Design, eligibility criteria and primary and secondary endpoints of the Phase II/III CYCLONE 2 trial evaluating first-line abiraterone and prednisone with or without abemaciclib for mCRPC; estimated completion date

MODULE 4: Best Practice Management of mCRPC for Patients Harboring HRR Gene Alterations

  • Incidence of BRCA1/2 and other HRR abnormalities in patients with prostate cancer; indications for and practical implementation of genetic testing
  • Mechanistic similarities and differences between approved (eg, olaparib, rucaparib) and investigational (eg, talazoparib, niraparib) PARP inhibitors with documented efficacy in patients with mCRPC; implications for activity and tolerability
  • Available data with PARP inhibitor monotherapy for mCRPC (from the PROfound, TRITON2, TRITON3, GALAHAD and TALAPRO-1 trials)
  • FDA-approved indications for olaparib and rucaparib for mCRPC; optimal integration into disease management algorithms
  • Key findings from the Phase III PROpel and MAGNITUDE trials among patients with HRR gene alterations
  • Implications of emerging findings from the Phase III TALAPRO-2 study for the management of mCRPC with HRR gene mutation

MODULE 5: Current and Emerging Therapeutic Strategies for Recurrent mCRPC

  • Available data with, ongoing evaluation of and patient selection for radium-223
  • Key efficacy and safety data from the Phase III VISION study evaluating 177Lu-PSMA-617 for progressive PSMA-positive mCRPC
  • Emerging findings from the Phase III PSMAfore trial comparing 177Lu-PSMA-617 to a change in androgen receptor (AR)-directed therapy for patients with mCRPC previously treated with an alternate AR pathway inhibitor but not exposed to taxane-containing chemotherapy
  • Efficacy and safety data from the CARD study and other recent trials investigating cabazitaxel for mCRPC
  • Appropriate integration of cabazitaxel into the current mCRPC treatment algorithm and practical considerations for its use
  • Preliminary findings from the mCRPC cohort of the Phase Ib COSMIC-021 trial evaluating cabozantinib with atezolizumab
  • Design, eligibility criteria and key efficacy and safety endpoints of the Phase III CONTACT-02 trial of cabozantinib with atezolizumab for mCRPC

Target Audience
This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appraise published research and current guidelines for the optimal management of prostate cancer for patients with biochemical recurrence after local treatment, and counsel appropriate candidates regarding the potential benefits of systemic therapy.
  • Evaluate published research supporting the FDA approvals of secondary hormonal agents for the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the discussion of nonresearch treatment options.
  • Explore available data with cytotoxic therapy, secondary hormonal therapy or combinations of these for metastatic hormone-sensitive prostate cancer, and integrate these strategies into clinical management algorithms.
  • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for metastatic CRPC (mCRPC), considering patient age, comorbidities, prior therapeutic exposure and other clinical and biologic factors.
  • Assess the available research supporting the use of PARP inhibitor monotherapy for mCRPC with a homologous recombination repair (HRR) gene alteration, and discern how to optimally incorporate these agents into current treatment algorithms.
  • Develop an understanding of the rationale for, available and emerging data with and ongoing research evaluating PARP inhibitors in combination with androgen receptor-targeted therapy, and consider the potential role of these novel regimens for patients with and without HRR gene mutations.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Antonarakis — Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Sanofi; Consulting Agreements: AIkido Pharma Inc, Blue Earth Diagnostics, Clovis Oncology, CM Propel, EcoR1 Capital LLC, Exact Sciences Corporation, Foundation Medicine, KeyQuest Health, Orion Corporation, Tempus; Contracted Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Clovis Oncology; Patent Holder: QIAGEN; Nonrelevant Financial Relationship: Ismar Healthcare NV, Projects in Knowledge. Prof Fizazi — Advisory Board (Honoriaria to Me): CureVac, Orion Corporation; Advisory Board or Speaking Engagements (Honoraria Provided to My Institution): Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Daiichi Sankyo Inc, Janssen Biotech Inc, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Sanofi. Dr Hussain — Contracts for Clinical Trials with Northwestern University: Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group; Honoraria — Advisory Boards: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Convergent Therapeutics Inc, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Pfizer Inc, Tempus; Invited Speaker by International Specialty Societies (Brazil, India, Israel, Korea, Malaysia): Astellas, AstraZeneca Pharmaceuticals LP; Nonrelevant Financial Relationship (Educational Lectures): Clinical Care Options, Great Debates and Updates in GU Oncology, Medscape, Medscape Zero, MJH Life Sciences, Precisca. Dr Smith — Advisory Committee and Consulting Agreements: Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc; Contracted Research (to Institution): Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc.

MODERATOR — Alan H Bryce, MD – No relevant conflicts of interest to disclose.

RESEARCH TO PRACTICE PRESIDENT NEIL LOVE, MD — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Merck, and Sanofi.

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Meeting Room
Yerba Buena – Salon 7 (Lower B2 Level)

Directions
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Convention Center, where the 2023 ASCO Genitourinary Cancers Symposium is taking place.

 
This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of prostate cancer.

​ There is no fee to participate in this hybrid event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.

​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

In-Person Registration for clinicians in practice »
 
IN-PERSON registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

In-Person Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2023 ASCO Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.